Loading organizations...
Loading organizations...
Key people at HOPU Investments.
HOPU Investments operates as a prominent alternative asset manager. Its core function involves strategic private equity investments, seeking out and deploying capital into significant companies across global markets. This approach aims to foster growth and transformation within its portfolio entities by providing essential capital and strategic guidance.
Established in 2008, HOPU was founded by Fang Fenglei. The firm's inception stemmed from the founding team's extensive experience and instrumental involvement in Asia's economic development over prior decades. This profound insight into regional market dynamics and growth potential informed its foundational investment philosophy, focusing on impactful capital deployment.
HOPU primarily serves as a capital partner to influential companies seeking substantial investment for expansion and strategic initiatives. The company's long-term vision centers on identifying and supporting transformative opportunities globally. It aims to contribute to the evolution of industries and markets through its discerning investment strategies and commitment to value creation.
Key people at HOPU Investments.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 24, 2021 | Lyndra Therapeutics | $60.5M Series C | Geoffrey Cornell, CFA | Catalytic Impact Foundation, Gilead Sciences, Invus, Limitless Ventures, Mass General Brigham Ventures, Polaris Partners, Quark Venture, Yipinhong Pharmaceutical (USA) |
| Jul 23, 2019 | Trax | $100.0M Series D | Gunther Hamm | — |
| Jan 29, 2019 | Lyndra Therapeutics | $55.0M Series B | — | Bill & Melinda Gates Foundation, Gilead Sciences, Cliff Chau, Invus, Orient Life, Polaris Partners |
| Jun 29, 2018 | I-Mab Biopharma | $220.0M Mab Biopharma - Series C | Hony Capital | Ally Bridge Group, C-Bridge Capital, CDH Investments, EDBI, Hillhouse Capital |
| Aug 5, 2016 | Ambrx | $45.0M Other Equity | Apricot Capital, Northeast Securities | China Everbright, Fosun Pharma, Sinopharm Capital |